Obeldesivir
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Obeldesivir
- Molecular weight
- 361.36
- Structure (SMILES)
- CC(C)C(=O)OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O
- 2 c 4 aminopyrrolo 2 1 f 1 2 4 triazin 7 yl 2 5 anhydro d altrononitrile 6 2 methylpropanoate
- 2-C-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D -altrononitrile 6-(2-methylpropanoate)
- atv 006
- ATV-006
- atv006
- ATV006
- gs 5245
- GS-5245
- obeldesivir
- Obeldesivir
- obeldesivir [INN]
- OBELDESIVIR [USAN]
- Obeldesivir [WHO-DD]
- obeldesivir inn
- obeldesivir usan
- obeldesivir who dd
- CAS registry numbers
- 2647441-36-7
- ChEMBL ID
- CHEMBL4863829
- InChIKey
- YIHPGVCWGSURHO-VSBTWAGUSA-N
- PubChem compound IDs
- 162513664
- FDA ingredient codes (UNII)
- Q55KCM7PXB
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- obeldesivir
- Type
- Synthetic organic
- Drug name stem
- -vir
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- MONDO_0001577
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05603143
- NCT05715528
- NCT05996744
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 3
- Polar surface area
- 155.99
- Calculated partition coefficient (ALogP)
- -0.65
- Calculated partition coefficient (XLogP)
- -0.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 26
- Molecular formula
- C16H19N5O5
- Monoisotopic mass
- 361.13861872
- Natural product
- No
- Recorded assays
- 132
- Active assays
- 20
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (6)
- Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease
- Study of Obeldesivir in Children and Adolescents With COVID-19
- Study of Obeldesivir in Nonhospitalized Participants With COVID-19
- Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
- Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
- Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
In development for (1)
- COVID-19 Phase 3